Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Rising prices of...

    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2020-04-14T14:52:59+05:30  |  Updated On 14 April 2020 2:52 PM IST
    Rising prices of hydroxychloroquine raw material forces small scale pharmas in Haridwar to stop production

    The raw materials which earlier used to cost Rs 9,000 per kilogram are now being sold at Rs 55,000-75,000

    Dehradun: While the demand for hydroxychloroquine tablets keeps on rising worldwide, small pharmaceutical manufacturers in Haridwar have stopped producing the drug due to the sharp increase in the cost of raw materials, according to Anil Sharma, President of the Pharmaceutical Manufacturer Association in Haridwar.

    "Many companies in Uttarakhand have the license for manufacturing hydroxychloroquine in Uttarakhand. However, the problem for us is that raw materials have become too costly. The raw materials which earlier used to cost Rs 9,000 per kilogram are now being sold at Rs 55,000-75,000. It is because the demand for raw materials is too high and the supply is low in the market, due to which the traders who have them are charging high prices," Sharma told here.

    "Further, the maximum selling price of the drug is controlled and it can be sold only at Rs 5.61, therefore, it is not possible for small companies in the MSME sector to manufacture it as our manufacturing price is working out to be more than the MRP," he added.

    The Pharmaceutical Manufacturer Association President further said that the MSME sector is willing to manufacture the drug if the issue of raw materials is sorted out.

    "Our Drug Controller has written to the Centre to ensure the availability of raw materials to our MSME sector pharma companies. If those raw materials arrive then we will definitely manufacture the drug and release it in the market," Sharma said.

    Meanwhile, speaking on the issue, Uttarakhand Drug Controller Tajbar Singh said that he has requested the Drug Controller General of India to ensure the supply of raw material.

    "Over 60 companies have been approved for the production of hydroxychloroquine here. But there is a shortage in the supply of raw materials. Production will begin as soon as raw material reaches. Have written to Drug Controller General of India on it," Singh said.

    Read also: Hydroxychloroquine Not Approved As Anti-Malarial Drug In India, Says Ipca Laboratories Joint MD

    hydroxychloroquinecoronaviruscovid-19
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok